EA201992684A1 - Материалы и способы конструирования клеток и пути их применения в иммуноонкологии - Google Patents

Материалы и способы конструирования клеток и пути их применения в иммуноонкологии

Info

Publication number
EA201992684A1
EA201992684A1 EA201992684A EA201992684A EA201992684A1 EA 201992684 A1 EA201992684 A1 EA 201992684A1 EA 201992684 A EA201992684 A EA 201992684A EA 201992684 A EA201992684 A EA 201992684A EA 201992684 A1 EA201992684 A1 EA 201992684A1
Authority
EA
Eurasian Patent Office
Prior art keywords
methods
materials
immununology
ways
application
Prior art date
Application number
EA201992684A
Other languages
English (en)
Inventor
Джонатан Александер Терретт
Деметриос Калаицидис
Лоуренс Клейн
Original Assignee
Криспр Терапьютикс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Криспр Терапьютикс Аг filed Critical Криспр Терапьютикс Аг
Priority claimed from PCT/IB2018/001619 external-priority patent/WO2019097305A2/en
Publication of EA201992684A1 publication Critical patent/EA201992684A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/001138—Tumor necrosis factors [TNF] or CD70
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70539—MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells

Abstract

Материалы и способы получения клеток с отредактированным геномом, сконструированных для экспрессии конструкции химерного антигенного рецептора (CAR) на поверхности клетки, и материалы и способы редактирования генома для модулирования экспрессии, функции или активности одного или нескольких генов клетки, связанных с иммуноонкологией, а также материалы и способы лечения пациента с применением сконструированных клеток с отредактированным геномом.
EA201992684A 2018-04-10 2018-05-11 Материалы и способы конструирования клеток и пути их применения в иммуноонкологии EA201992684A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862655510P 2018-04-10 2018-04-10
PCT/IB2018/001619 WO2019097305A2 (en) 2017-05-12 2018-05-11 Materials and methods for engineering cells and uses thereof in immuno-oncology

Publications (1)

Publication Number Publication Date
EA201992684A1 true EA201992684A1 (ru) 2020-06-23

Family

ID=71138808

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992684A EA201992684A1 (ru) 2018-04-10 2018-05-11 Материалы и способы конструирования клеток и пути их применения в иммуноонкологии

Country Status (1)

Country Link
EA (1) EA201992684A1 (ru)

Similar Documents

Publication Publication Date Title
SA519410518B1 (ar) مواد وطرق لمعالجة الخلايا بالهندسة الوراثية واستخداماتها في علم العلاج المناعي للوقاية من الأمراض السرطانية
EA202091339A1 (ru) Антитела против cd47 и их применение для лечения онкологических заболеваний
WO2019222275A3 (en) Compositions and methods for tcr reprogramming using inducible fusion proteins
MX2018012729A (es) Materiales y metodos para el tratamiento de hemoglobinopatias.
NZ765695A (en) Immune cell organoid co-cultures
MX2018005332A (es) Materiales y metodos para tratamiento de la enfermedad de almacenamiento de glucogeno tipo 1a.
EA202191463A1 (ru) Мультиплексное редактирование генома иммунных клеток для повышения функциональности и устойчивости к подавляющей среде
EA201992795A1 (ru) Способ получения эукариотических клеток с отредактированной днк и набор, используемый в этом способе
EA202090931A3 (ru) Композиции и способы перепрограммирования tcr с помощью гибридных белков
EA201791443A1 (ru) Естественные киллерные клетки и их применения
SG10201902574RA (en) Adeno-associated virus vector variants for high efficiency genome editing and methods thereof
MX2020009371A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión.
MX2021006932A (es) Receptores de celulas t humanas con alta afinidad modificados por medio de manipulacion genetica.
MX2021010556A (es) Animales no humanos que tienen un locus de la cadena ligera lambda de inmunoglobulina modificado geneticamente.
AU2015311681A8 (en) Globin gene therapy for treating hemoglobinopathies
MX2020004541A (es) Edicion de genes de celulas primarias.
MX2020005830A (es) Animales no humanos que tienen una cadena ligera lambda de inmunoglobulina modificada y usos de estos.
MX2021013713A (es) Celulas pluripotentes modificadas.
MX2021001009A (es) Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión específicas de la diana.
TR201901668T4 (tr) Sınırlı bir immünoglobulin hafif zincir repertuvarını eksprese eden fareler.
CO2021012719A2 (es) Métodos para producción de células car-nk y uso de las mismas
BR112021014645A2 (pt) Método de edição de genes
AR116048A1 (es) Composiciones y métodos para reprogramar receptores de células t (tcr) usando proteínas de fusión
MX2022005815A (es) Terapia para neoplasias malignas de celulas hematopoyeticas utilizando linfocitos t modificados geneticamente que se dirigen a cd70.
EP3765070A4 (en) SPECIFICALLY MODIFIED CELLS, T-LYMPHOCYTE IMMUNE MODULATION ANTIBODIES AND THEIR USE PROCEDURES